Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENA: SSR149415 in Major Depressive Disorder
NCT00361491Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Primary completion
- Sep 2007
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of nelivaptan in major depressive disorder (MDD) (4 arms), sponsored by Sanofi. Primary endpoint: 17-item Hamilton Depression Rating Scale at Day 56. Started Aug 2006; status: completed.
02
Drugs
nelivaptan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00361491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361491.